secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001641172-25-000987
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wellgistics grants 19.8M shares of restricted stock; reports pro forma 2024 revenue of $45.7M
--------------------------------------------------------------------------------

- Granted 19,764,108 restricted shares under the 2023 Equity Plan, including 9M to CEO vesting on financial metrics for FY2025-2027.
- Pro forma consolidated net sales for 2024 were $45.7M, a 33% increase over 2023, assuming recent acquisitions occurred Jan 1, 2023.
- Launched EinsteinRx, an AI-driven decision support software integrated into the Wellgistics Hub prescription platform.
- Aims to onboard 5,000 pharmacies by mid-2026 and grow active patient base 10x by year-end.
- Plans multiple tech-driven acquisitions and predictive care AI for customer service and benefits verification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000164117225000987/0001641172-25-000987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000164117225000987/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer